Evidence map›Paper›PMID 27286459›Full record

ArticleOncotarget2016

Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Takashi Murakami, Arun S Singh, Tasuku Kiyuna, Sarah M Dry, Yunfeng Li, Aaron W James, Kentaro Igarashi, Kei Kawaguchi, Jonathan C DeLong, Yong Zhang and 12 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
25.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Precision medicine in Ewing sarcoma: a translational point of view.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 2 countries.

Takashi MurakamiAntiCancer, Inc., San Diego, CA, USA.
Arun S SinghDivision of Hematology-Oncology, University of California, Los Angeles, CA, USA.
Tasuku KiyunaAntiCancer, Inc., San Diego, CA, USA.
Sarah M DryDepartment of Pathology, University of California, Los Angeles, CA, USA.
Yunfeng LiDepartment of Pathology, University of California, Los Angeles, CA, USA.
Aaron W JamesDepartment of Pathology, University of California, Los Angeles, CA, USA.
Kentaro IgarashiAntiCancer, Inc., San Diego, CA, USA.
Kei KawaguchiAntiCancer, Inc., San Diego, CA, USA.
Jonathan C DeLongDepartment of Surgery, University of California, San Diego, CA, USA.
Yong ZhangAntiCancer, Inc., San Diego, CA, USA.
Yukihiko HiroshimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Tara RussellDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Mark A EckardtDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Jane YanagawaDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Noah FedermanDepartment of Pediatrics and Department of Orthopaedics, University of California, Los Angeles, CA, USA.
Ryusei MatsuyamaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Takashi ChishimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Kuniya TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Michael BouvetDepartment of Surgery, University of California, San Diego, CA, USA.
Itaru EndoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Fritz C EilberDivision of Surgical Oncology, University of California, Los Angeles, CA, USA.
Robert M HoffmanAntiCancer, Inc., San Diego, CA, USA.
University of California, Los Angeles · USAntiCancer (United States) · USYokohama City University · JPUniversity of California, San Diego · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing's sarcoma is a rare and aggressive malignancy. In the present study, tumor from a patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion was implanted in the right chest wall of nude mice to establish a patient-derived orthotopic xenograft (PDOX) model. The aim of the present study was to determine efficacy of cyclin-dependent kinase 4/6 (CDK4/6) and insulin-like growth factor-1 receptor (IGF-1R) inhibitors on the Ewing's sarcoma PDOX. The PDOX models were randomized into the following groups when tumor volume reached 50 mm3: G1, untreated control; G2, doxorubicin (DOX) (intraperitoneal (i.p.) injection, weekly, for 2 weeks); G3, CDK4/6 inhibitor (palbociclib, PD0332991, per oral (p.o.), daily, for 14 days); G4, IGF-1R inhibitor (linsitinib, OSI-906, p.o., daily, for 14 days). Tumor growth was significantly suppressed both in G3 (palbociclib) and in G4 (linsitinib) compared to G1 (untreated control) at all measured time points. In contrast, DOX did not inhibit tumor growth at any time point, which is consistent with the failure of DOX to control tumor growth in the patient. The results of the present study demonstrate the power of the PDOX model to identify effective targeted molecular therapy of a recalcitrant DOX-resistant Ewing's sarcoma with specific genetic alterations. The results of this study suggest the potential of PDOX models for individually-tailored, effective targeted therapy for recalcitrant cancer.

Indexed as

Molecular Targeted TherapyAnimalsBone NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18DoxorubicinDrug Resistance, NeoplasmFemaleHumansImidazolesMiceOncogene Proteins, FusionPiperazinesPyrazines3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanolCDKN2A protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p18DoxorubicinImidazolesOncogene Proteins, FusionpalbociclibPiperazinesPyrazinesPyridinesReceptor, IGF Type 1RNA-Binding Protein FUSTLS-ERG fusion protein, humanEwing’s sarcomalinsitinibpalbociclibpatient-derived orthotopic xenograftPDOX

Identifiers

PMID27286459
PMCPMC5216960
OpenAlexW2419037363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.